
Chemed (CHE) Stock Forecast & Price Target
Chemed (CHE) Analyst Ratings
Bulls say
Chemed is attractive because 3Q26 showed both revenue and earnings momentum, with consolidated EBITDA and adjusted EPS ahead of estimates and share performance reflecting confidence in execution. VITAS remains the core driver, as revenue rose 12.2% to $457.4MM, ADC grew 9.4%, and adjusted EBITDA margin expanded to 20.2% ex-Medicare cap, while a $34MM Florida cap cushion and no anticipated FY27 cap liability reduce risk. Roto-Rooter is still pressured by higher marketing costs, but 7.5% revenue growth, improving water-restoration metrics, and management’s expectation that FY26 EPS can meet or exceed $25.75 support a constructive outlook on longer-term earnings power.
Bears say
Chemed is facing a negative fundamental setup because over 90% of VITAS revenue depends on Medicare and Medicaid, leaving earnings vulnerable to reimbursement pressure, Medicare cap risk, and heightened regulatory scrutiny in a highly investigated industry. On the Roto-Rooter side, softer consumer demand in 2027, persistent marketing pressure, and a higher mix of paid leads are likely to weigh on margins, while weaker discretionary plumbing demand could further slow results during an economic downturn. The company’s recent $96M in franchise reacquisitions, including $62.5M in California, also carries integration and ramp risk, with management expecting California to generate only $30-$35M of revenue and less than $4M of EBITDA in 2027.
This aggregate rating is based on analysts' research of Chemed and is not a guaranteed prediction by Public.com or investment advice.
Chemed (CHE) Analyst Forecast & Price Prediction
Start investing in Chemed (CHE)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Chemed (CHE) Forecast
Chemed (CHE) Analyst Forecast & Price Prediction
Start investing in Chemed (CHE)
Order type
Buy in
Order amount
Est. shares
0 shares